Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3537031 in Overweight and Obese Participants and Healthy Volunteers
NCT06606106Phase 1Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2024
- Primary completion
- Nov 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LY3537031 in obesity and Overweight (8 arms), sponsored by Eli Lilly and Company. Primary endpoint: Adverse Events at 56 weeks. Started Sep 2024; status: active, not recruiting.
02
Drugs
LY3537031
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT06606106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06606106.